" class="no-js "lang="en-US"> Osso VR - Medtech Alert
Monday, September 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Osso VR | Pharmtech Focus

Osso VR

About Osso VR

Osso VR

Osso VR is a surgical training and assessment platform that gives medical device companies and healthcare professionals radically better ways to share, practice and learn new skills and procedures. From rare to routine, simple to the most complex.

Related Story

Fundraising

 Osso VR Raises $66 Million to Broaden Access to Surgical Education for Healthcare Professionals | Pharmtech Focus

Osso VR Raises $66 Million to Broaden Access to Surgical Education for Healthcare Professionals

March 25 2022

Osso VR, a validated virtual reality (VR) surgical training and assessment platform, today announced that […]